AUD 0.01
(0.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 | 1606.00 AUD | 93.28% |
2023 | -824.86 Thousand AUD | 10.59% |
2022 | -922.59 Thousand AUD | -1821.92% |
2021 | -48 Thousand AUD | 75.54% |
2020 | -196.23 Thousand AUD | -2099.9% |
2019 | -8920.00 AUD | 57.43% |
2018 | -20.95 Thousand AUD | -1.24% |
2017 | -20.69 Thousand AUD | -146.5% |
2016 | 44.51 Thousand AUD | 103.2% |
2015 | 21.9 Thousand AUD | -85.44% |
2014 | 150.46 Thousand AUD | 170.02% |
2013 | 55.72 Thousand AUD | -96.53% |
2012 | 1.6 Million AUD | 43.92% |
2011 | 1.11 Million AUD | -74.95% |
2010 | 4.45 Million AUD | 325.0% |
2009 | 1.04 Million AUD | 719.09% |
2008 | 127.9 Thousand AUD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -1.03 Million AUD | 0.0% |
2024 FY | -1.62 Million AUD | -97.02% |
2024 Q4 | -591.58 Thousand AUD | 0.0% |
2023 Q2 | -116.12 Thousand AUD | 0.0% |
2023 Q4 | -708.73 Thousand AUD | 0.0% |
2023 FY | -824.86 Thousand AUD | 10.59% |
2022 Q2 | -464.99 Thousand AUD | 0.0% |
2022 Q4 | -457.6 Thousand AUD | 0.0% |
2022 FY | -922.59 Thousand AUD | -1821.92% |
2021 Q2 | -51.21 Thousand AUD | 0.0% |
2021 FY | -48 Thousand AUD | 75.54% |
2021 Q4 | 3214.00 AUD | 0.0% |
2020 Q4 | -178.38 Thousand AUD | 0.0% |
2020 Q2 | -17.84 Thousand AUD | 0.0% |
2020 FY | -196.23 Thousand AUD | -2099.9% |
2019 Q2 | - AUD | 0.0% |
2019 Q4 | -4917.00 AUD | 0.0% |
2019 FY | -8920.00 AUD | 57.43% |
2018 FY | -20.95 Thousand AUD | -1.24% |
2018 Q2 | - AUD | 0.0% |
2018 Q4 | - AUD | 0.0% |
2017 Q2 | - AUD | 0.0% |
2017 FY | -20.69 Thousand AUD | -146.5% |
2016 FY | 44.51 Thousand AUD | 103.2% |
2016 Q2 | - AUD | 0.0% |
2015 Q2 | 94.28 Thousand AUD | 0.0% |
2015 FY | 21.9 Thousand AUD | -85.44% |
2014 Q1 | 13.93 Thousand AUD | 0.0% |
2014 FY | 150.46 Thousand AUD | 170.02% |
2014 Q4 | -645.58 Thousand AUD | -1816.31% |
2014 Q3 | 37.61 Thousand AUD | -56.1% |
2014 Q2 | 85.67 Thousand AUD | 515.05% |
2013 Q3 | 13.93 Thousand AUD | -80.23% |
2013 FY | 55.72 Thousand AUD | -96.53% |
2013 Q4 | 13.93 Thousand AUD | 0.0% |
2013 Q2 | 70.44 Thousand AUD | -66.29% |
2013 Q1 | 208.95 Thousand AUD | 0.0% |
2012 Q2 | 208.95 Thousand AUD | 110.78% |
2012 Q3 | 208.95 Thousand AUD | 0.0% |
2012 Q4 | 208.95 Thousand AUD | 0.0% |
2012 FY | 1.6 Million AUD | 43.92% |
2012 Q1 | 99.13 Thousand AUD | 0.0% |
2011 FY | 1.11 Million AUD | -74.95% |
2011 Q1 | 167 Thousand AUD | 0.0% |
2011 Q3 | 99.13 Thousand AUD | 0.0% |
2011 Q4 | 99.13 Thousand AUD | 0.0% |
2011 Q2 | 99.13 Thousand AUD | -40.64% |
2010 Q2 | 167 Thousand AUD | 31.96% |
2010 Q3 | 167 Thousand AUD | 0.0% |
2010 Q1 | 126.55 Thousand AUD | 0.0% |
2010 Q4 | 167 Thousand AUD | 0.0% |
2010 FY | 4.45 Million AUD | 325.0% |
2009 Q1 | -42.82 Thousand AUD | 0.0% |
2009 Q4 | 126.55 Thousand AUD | 0.0% |
2009 FY | 1.04 Million AUD | 719.09% |
2009 Q3 | 126.55 Thousand AUD | 0.0% |
2009 Q2 | 126.55 Thousand AUD | 395.5% |
2008 Q3 | -42.82 Thousand AUD | 0.0% |
2008 FY | 127.9 Thousand AUD | 0.0% |
2008 Q4 | -42.82 Thousand AUD | 0.0% |
2008 Q2 | -42.82 Thousand AUD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
EZZ Life Science Holdings Limited | 50.94 Million AUD | 99.997% |
Anatara Lifesciences Ltd | -748.91 Thousand AUD | 100.214% |
Zelira Therapeutics Limited | 10.28 Thousand AUD | 84.384% |
Biome Australia Limited | 7.66 Million AUD | 99.979% |
Patrys Limited | 1.39 Million AUD | 99.885% |
Orthocell Limited | 3.68 Million AUD | 99.956% |
Imugene Limited | -5.83 Million AUD | 100.028% |
Noxopharm Limited | -534.81 Thousand AUD | 100.3% |
PYC Therapeutics Limited | 22.05 Million AUD | 99.993% |
Chimeric Therapeutics Limited | 7.45 Million AUD | 99.978% |
Prescient Therapeutics Limited | 3.71 Million AUD | 99.957% |
Proteomics International Laboratories Limited | -1.12 Million AUD | 100.143% |
Cynata Therapeutics Limited | 2.31 Million AUD | 99.931% |
CSL Limited | 15.28 Billion AUD | 100.0% |
Arovella Therapeutics Limited | -25.97 Thousand AUD | 106.182% |
Bio-Gene Technology Limited | -301.44 Thousand AUD | 100.533% |
Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 99.998% |
Starpharma Holdings Limited | 7.65 Million AUD | 99.979% |
Nanollose Limited | -348.95 Thousand AUD | 100.46% |
Invex Therapeutics Ltd | 1.21 Million AUD | 99.868% |
NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 101.758% |
Amplia Therapeutics Limited | 4.01 Million AUD | 99.96% |
Botanix Pharmaceuticals Limited | -6.55 Million AUD | 100.025% |
Island Pharmaceuticals Limited | 1.25 Million AUD | 99.872% |
Race Oncology Limited | 1.38 Million AUD | 99.884% |
Nyrada Inc. | -5164.07 AUD | 131.1% |
Telix Pharmaceuticals Limited | 308.5 Million AUD | 99.999% |
Dimerix Limited | 583.47 Thousand AUD | 99.725% |
PharmAust Limited | -1641.00 AUD | 197.867% |
Immutep Limited | 1.44 Million AUD | 99.889% |
Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 99.986% |
Alterity Therapeutics Limited | 3.8 Million AUD | 99.958% |
BTC Health Limited | 16.36 Thousand AUD | 90.183% |
Acrux Limited | -1.28 Million AUD | 100.125% |
Neuren Pharmaceuticals Limited | 205.17 Million AUD | 99.999% |
Biotron Limited | -40.49 Thousand AUD | 103.966% |
Tissue Repair Ltd | 150.51 Thousand AUD | 98.933% |
AdAlta Limited | 1.5 Million AUD | 99.893% |
Radiopharm Theranostics Limited | -21.3 Million AUD | 100.008% |
Hexima Limited | - AUD | -Infinity% |
AnteoTech Limited | 460.39 Thousand AUD | 99.651% |
Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | 97.173% |
Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 100.438% |
Avecho Biotechnology Limited | -43.79 Thousand AUD | 103.667% |
Actinogen Medical Limited | 9.93 Million AUD | 99.984% |
Immuron Limited | 3.33 Million AUD | 99.952% |
Argenica Therapeutics Limited | 2.59 Million AUD | 99.938% |